TickerFacts.

Intellia Therapeutics, Inc. (NTLA): EPS (Basic)

Annual figures by period end, from SEC filings.

-$3.81
Year ended 2025-12-31
2020-12-31: -$2.402021-12-31: -$3.782022-12-31: -$6.162023-12-31: -$5.422024-12-31: -$5.252025-12-31: -$3.81-$3.81
2020-12-31 EPS (Basic) (USD per share) 2025-12-31
Period endedEPS (Basic)Change YoYSource filing
2025-12-31-$3.81n/m2026-02-26, From 2025-01-01
2024-12-31-$5.25n/m2026-02-26, From 2024-01-01
2023-12-31-$5.42n/m2026-02-26, From 2023-01-01
2022-12-31-$6.16n/m2025-02-27, From 2022-01-01
2021-12-31-$3.78n/m2024-02-22, From 2021-01-01
2020-12-31-$2.40n/a2023-02-23, From 2020-01-01

EPS (Basic) at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEPS (Basic)Change YoY
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$3.81n/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$0.32n/m
Immucell Corp (ICCC)2025-12-31-$0.12n/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$0.37n/m
Anbio Biotechnology (NNNN)2025-12-31$0.15+162.5%
Myriad Genetics Inc (MYGN)2025-12-31-$3.95n/m
Neogen Corp (NEOG)2026-05-31-$0.04n/m
Biomerica Inc (BMRA)2026-05-31-$1.30n/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$1.65n/m

Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗